Comparison of complications of pentavalent and DTP vaccination in infants aged 2-6 months in Anzali, Iran

Document Type: Original Article


1 Pediatrics Growth Disorders Research Center, 17th Shahrivar Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

2 School of Medicine, Guilan University of Medical Sciences, Rasht, Iran


Background: Despite the efforts to enhance hygiene education and personal hygiene and use of antibiotics and vaccination, infectious diseases remain the second cause of mortality worldwide. Vaccination is one of the greatest medical achievements in the prevention of mortality and morbidity, which has decreased treatment costs. This study aimed to compare the complications caused by pentavalent and diphtheria-tetanus-pertussis (DTP) vaccination in infants aged 2-6 months.
Methods: This analytical cross-sectional study was conducted on all the infants aged 2-6 months referred to the healthcare centers of Anzali, Iran. Demographic data and complications of vaccination were collected from all the samples. Data analysis was performed using descriptive statistics, Fisher's exact test, Chi-square, and Mann-Whitney U test, and logistic regression analysis in SPSS.
Results: In total, 353 infants, including 163 female (46.2%) and 190 male (53.8%), were enrolled in this study. According to the results, 229 infants (64.9%) presented with vaccination complications. Fewer side effects were noted in infants receiving pentavalent vaccination compared to those receiving DTP vaccination (P=0.38). In order of occurrence, the most common complications of DTP vaccination were fever, excessive crying, and fussiness, respectively. Moreover, a significant correlation was observed between the used milk by infants and the extent of complications caused by vaccination in the pentavalent group (P=0.037).
Conclusion: According to the results of this study, application of pentavalent vaccination not only minimizes the local reactions, but it also diminishes local discomfort through reducing the number of injections. Therefore, infants receiving this type of vaccination encounter minimum local reactions. It is recommended that further investigation be conducted on larger sample sizes in multiple healthcare centers.


  1. World Health Organization. The world health report 2000: health systems: improving performance. Geneva: World Health Organization; 2000.
  2. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32(5):675–85.
  3. World Health Organization. The world health report 1999: making a difference: message from the Director-General. Geneva: World Health Organization; 1999.
  4. Centers for Disease Control and Prevention (CDC). Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morb Mortal Wkly Rep. 2006; 55(18):511-5.
  5. Zarei S, Jedi Tehrani M, Zarnani AH, Zeraati H, Bonakdar S, Ghazanfari M, et al. Early complications of DTP vaccination in 4-6years children of Tehran. Payesh. 2007; 6(3):273-83.
  6. Pentavalent vaccine guideline for health worker. Ministry of Health and Medical Education (Iran). Available at: URL: news/; 2015.
  7. World Health Organization. Life in the 21st century: a vision for all: the World Health Report. Geneva: World Health Organization; 1998.
  8. Pentavalent vaccine. Guideline for health worker with Answers to frequently asked questions. India: Ministry of Health and Family Welfare Government of India; 2012.
  9. Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine. Rev Panam Salud Publica. 2002; 12(4):247-57.
10. WHO vaccine-preventable diseases: monitoring system. 2015 global summary. World Health Organization. Available at: URL. immunization_monitoring/globalsummary/schedules; 2013.

11. Malik A. Pentavalent vaccine and adverse events following immunization-untangling the misinter-pretations. Indian J Pediatr. 2014; 81(12):1353–7.

12. Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999; 48(12):241-3.

13. Chirico G, Marconi M, De Amici M, Gasparoni A, Mingrat G, Chiara A, et al. Deficiency of neutrophil bactericidal activity in term and preterm infants. Biol Neonate. 1985; 47(3):125-9.

14. Hanson LA, Dahlman-Hoglund A, Lundin S, Karlsson M, Dahlgren U, Ahlstedt S, et al. The maturation of the immune system. Monogr Allergy. 1996; 32:10-5.

15. Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001; 19(25-26):3331-46.

16. Puliyel J. AEFI and the pentavalent vaccine: looking for a composite picture. Indian J Med Ethics. 2013; 10(3):142–6.

17. Tre T. Vietnam suspends Quinvaxem vaccine following 9 deaths. Available at: URL: http://; 2013.

18. Cunha MP, Dórea JG, Marques RC, Leão RS. Vaccine adverse events reported during the first ten years (1998–2008) after introduction in the state of Rondonia, Brazil. BioMed Res Int. 2013; 2013:853083.

19. Karami M, Holakouie Naieni K, Rahimi A, Fotouhi A, Eftekhar Ardabili H. Adverse events following immunization with DTP vaccine in infants and children in Kermanshah city: a cohort study. Iran J Epidemiol. 2006; 1(3-4): 33-9 (Persian).

20. Mortimer Jr EA, Jones PK. Pertusis vaccine in the United States: the benefit-risk ratio. International symposium on pertussis. Bethesda: National Institutes of Health; 1979.

21. Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. S Afr Med J.2011; 101(2):126-31.

22. Sauer L. Whooping cough: a study in immunization. JAMA. 1993; 100(4):239-41.